The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy

BACKGROUND: Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to radiotherapy in the control of metastatic tumour growth. METHODS: The NLCQ-1, RB6145 and tirapazamine were assessed against the spontaneously metastasising KHT model. Subc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lunt, S J, Cawthorne, C, Ali, M, Telfer, B A, Babur, M, Smigova, A, Julyan, P J, Price, P M, Stratford, I J, Bloomer, W D, Papadopoulou, M V, Williams, K J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906743/
https://www.ncbi.nlm.nih.gov/pubmed/20588272
http://dx.doi.org/10.1038/sj.bjc.6605753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906743/
https://www.ncbi.nlm.nih.gov/pubmed/20588272
http://dx.doi.org/10.1038/sj.bjc.6605753

Ejemplares similares